Voices
Sanam Loghavi
Sanam Loghavi/faculty.mdanderson.org

Sanam Loghavi: Long-Term Outcomes in FLT3-m AML

Sanam Loghavi, Associate Professor of Pathology at MD Anderson Cancer Center, Medical Director of ECOG-ACRIN Leukemia Bank and Editor in Chief of Image Bank at the American Society of Hematology, shared a post on X:

“Long-term outcomes in FLT3-m AML with frontline HMA+VEN+FLT3 i

  • 93% CR/CRi in ND FLT3-m AML.
  • 3-yr OS: 45% (FLT3-ITD), 76% (FLT3-TKD).
  • RASp mutations poor survival.
  • ITD NGS MRD highly prognostic.
  • FLT3 wild-type relapses common.”

Sanam Loghavi

Title: Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitor

Authors: Nicholas J. Short, Sanam Loghavi, Musa Yilmaz, Omer Karrar, Kunhwa Kim, Courtney D. Dinardo, Tapan M. Kadia, Manuel Maroun, Gautam Borthakur, Ghayas C. Issa, Joseph Jabbour, Betul Oran, Elizabeth J. Shpall, Uday Popat, Keyur P. Patel, Mark Routbort, Marina Konopleva, Farhad Ravandi, Hagop Kantarjian, Naval Daver

Read the Full Article in haematologica.

Sanam Loghavi

More posts featuring Sanam Loghavi on OncoDaily.

Betül Oran cancer Courtney D. DiNardo Elizabeth J. Shpall Farhad Ravandi Gautam Borthakur Ghayas C. Issa Hagop Kantarjian Joseph Jabbour Keyur P. Patel Kunhwa Kim Manuel Maroun Marina Konopleva Mark Routbort Musa Yilmaz Naval Daver Nicholas J. Short Omer Karrar OncoDaily Oncology Sanam Loghavi Tapan M. Kadia Uday Popat